355 related articles for article (PubMed ID: 28708211)
1. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
Fabrizi F; Donato FM; Messa P
Int J Artif Organs; 2017 Oct; 40(10):531-541. PubMed ID: 28708211
[TBL] [Abstract][Full Text] [Related]
2. [Direct-acting antiviral agents, hepatitis C and dialysis: an update].
Fabrizi F; Lampertico P; Messa P
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234230
[TBL] [Abstract][Full Text] [Related]
3. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
Fabrizi F; Martin P; Messa P
Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
[TBL] [Abstract][Full Text] [Related]
4. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
5. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C
J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990
[TBL] [Abstract][Full Text] [Related]
8. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis.
Fabrizi F; Cerutti R; Dixit V; Ridruejo E
Nefrologia (Engl Ed); 2021; 41(5):578-589. PubMed ID: 36165141
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.
Ko SY; Choe WH
Clin Mol Hepatol; 2018 Dec; 24(4):351-357. PubMed ID: 29544240
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
Kikuchi K
Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
[TBL] [Abstract][Full Text] [Related]
12. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
Bruchfeld A; Lindahl K
Semin Dial; 2019 Mar; 32(2):135-140. PubMed ID: 30475421
[TBL] [Abstract][Full Text] [Related]
13. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Sorbera MA; Friedman ML; Cope R
J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
[TBL] [Abstract][Full Text] [Related]
14. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis c virus and chronic kidney disease.
Khan MU; Mahmoud MI; Butt AA
Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):579-590. PubMed ID: 32613874
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
Li T; Qu Y; Guo Y; Wang Y; Wang L
Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.
Kim SM; Song IH
Korean J Intern Med; 2018 Jul; 33(4):670-678. PubMed ID: 29961309
[TBL] [Abstract][Full Text] [Related]
18. [Novel antiviral agents for the treatment of HCV among renal transplant recipients].
Fabrizi F; Donato FM; Messa P
G Ital Nefrol; 2017 Aug; 34(4):35-50. PubMed ID: 28762681
[TBL] [Abstract][Full Text] [Related]
19. [Novel treatments for hepatitis C virus infection in chronic kidney disease].
Fabrizi F; Messa P
G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545640
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
Huang Y; Li MH; Hou M; Xie Y
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
